The company states: " Veru announces the results of today’s meeting of the U.S. Food and Drug Administration’s Pulmonary-Allergy Drugs Advisory Committee, which reviewed sabizabulin for Emergency Use Authorization in hospitalized moderate to severe COVID-19 patients who are at high risk for acute respiratory distress syndrome. The advisory committee voted 8-5 that the known and potential benefits of sabizabulin when used for the treatment of adult patients hospitalized with COVID-19 at high risk of ARDS do not outweigh the known and potential risks of sabizabulin. However, there was additional discussion around the clinical trial design aspects of an additional clinical trial as a potential post authorization requirement. FDA will consider the input of the advisory committee as part of their review of the EUA and render a decision on the Emergency Use Authorization."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on VERU:
- Veru Tanks After FDA Snub For COVID-19 Therapy
- Veru Provides Update on FDA Advisory Committee Meeting Regarding Emergency Use Authorization of Sabizabulin to Treat Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
- FDA Pulmonary-Allergy Drugs Advisory Committee to hold a virtual meeting
- Unusually active option classes on open November 8th
- Jefferies biotechnology analyst to hold an analyst/industry conference call
Questions or Comments about the article? Write to editor@tipranks.com